Thompson Davis & Co’s Genomic Health, Inc. GHDX Stock Holding History

Thompson Davis & Co’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$9K	Hold	125	–	–	0.02%	484
2018 Q2	$6K	Buy	+125	New	+$4.96K	0.01%	507

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Thompson Davis & Co's GHDX Position: Q3 2018 in Review

Thompson Davis & Co held its Genomic Health, Inc. (GHDX) position steady in Q3 2018 at 125 shares worth $9K. The position accounts for 0.02% of the portfolio, ranked #484.

Thompson Davis & Co first reported a position in GHDX in Q2 2018 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold GHDX as of Q3 2018.

Thompson Davis & Co held 125 shares of Genomic Health, Inc. worth $9K as of Q3 2018.
Thompson Davis & Co left its Genomic Health, Inc. share count unchanged in Q3 2018.
Genomic Health, Inc. made up 0.02% of Thompson Davis & Co's portfolio in Q3 2018, its #484 holding.
Thompson Davis & Co first reported a position in Genomic Health, Inc. in Q2 2018 and has held it in 2 quarters since.
201 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.